Tag

Investing

All articles tagged with #investing

Regulatory Headwinds Rebalance the Data Center Playbook Toward the Giants
business4 hours ago

Regulatory Headwinds Rebalance the Data Center Playbook Toward the Giants

CNBC’s Jim Cramer argues rising political opposition to data-center projects could slow the buildout and pressure valuations of traditional vendors, but tighter rules may primarily benefit hyperscalers—Amazon, Alphabet, Microsoft and Meta—who can absorb compliance costs and outcompete smaller developers, potentially reducing competition for land, labor and electricity.

Five Monthly Dividend Payers for Steady September Income
investing2 days ago

Five Monthly Dividend Payers for Steady September Income

An investing roundup highlights five US monthly dividend payers for September—Realty Income (O), Main Street Capital (MAIN), Agree Realty (ADC), STAG Industrial (STAG) and EPR Properties (EPR). Realty Income offers strong AFFO coverage and a high occupancy rate; Main Street confirms a September supplemental dividend and potential December payout; Agree Realty shows near-100% occupancy with raised AFFO guidance; STAG Industrial has shifted to quarterly dividends, weakening the monthly income appeal despite solid FFO growth; EPR Properties yields about 5.94% with AFFO coverage near 65% and robust leasing, though tenant concentration and debt maturities are risks. Together these provide a diversified monthly cash-flow ladder across net-lease retail, industrial and experiential assets, helping investors weather September volatility.

Rethinking 62: Is Early Social Security Worth It?
personal-finance2 days ago

Rethinking 62: Is Early Social Security Worth It?

The article weighs Dave Ramsey’s caution that taking Social Security at 62 and investing the checks may outperform waiting, against the guaranteed, inflation-adjusted increases from delaying benefits. It explains the break-even point—roughly age 80–82 per AARP data—where waiting surpasses early claiming in lifetime value, notes the risk of stock-market volatility, and highlights the impact on survivor benefits and the earnings test if you work before FRA. Bottom line: there’s no one-size-fits-all rule; plug your numbers into the Social Security site to tailor the decision based on health, cash needs, and life expectancy.

30-Year TIPS Reopening Yields 2.973% Real Return, Highest Since 2001
investing3 days ago

30-Year TIPS Reopening Yields 2.973% Real Return, Highest Since 2001

The Treasury reopened a 30-year TIPS, delivering a real yield to maturity of 2.973%—the highest for the term since 2001—after Treasury buybacks of long-term Treasuries briefly pushed yields lower before rebounding. The issue priced at 88.317, implying a $9,101.51 cost for a $10,000 par with an inflation index around 1.0306 and a 2.375% coupon; the 30-year inflation breakeven rate sits near 2.26%, suggesting long-run inflation protection. Investors see a near-zero real-risk return if held to maturity, though concerns about market manipulation and reinvestment risk temper the allure.

DZ Bank flags SpaceX valuation as potentially too rich for execution
finance3 days ago

DZ Bank flags SpaceX valuation as potentially too rich for execution

DZ Bank analyst Markus Leistner initiated coverage of SpaceX (SPCX) with a Sell rating and a $100 fair value, signaling roughly 25% downside from recent trading. He warns that SpaceX’s ambitious Space, Starlink and AI businesses are capital-intensive, and the current valuation may outpace near-term execution. In Q2, SpaceX revenue rose 92% to $7.8B and adjusted EBITDA nearly tripled to $3.5B, but quarterly capex reached $18.4B (AI capex $15.8B). After IPO proceeds and a $25B bond, SpaceX sits on about $100B in cash/equivalents. The core question is whether faster growth and moderating capex can translate into cash flow to justify the valuation, with investors watching AI spend, Starlink growth, connectivity margins, operating cash flow, and Starship progress; further financing or share unlocks could tilt the bear case.

Moderna’s Cancer Vaccine Breakthrough Triggers Massive Rally, Then Profit-Taking
investing4 days ago

Moderna’s Cancer Vaccine Breakthrough Triggers Massive Rally, Then Profit-Taking

Moderna’s personalized cancer vaccine mRNA-4157 (intismeran autogene) paired with Merck’s Keytruda hit key Phase 3 melanoma endpoints, delivering a 49% reduction in recurrence or death versus Keytruda alone and sparking a 177% one‑day stock surge before shares retraced about 20% as investors took profits; Moderna’s pipeline spans nine Phase 2/3 studies across melanoma, NSCLC, bladder and kidney cancers, despite a $950 million settlement and a norovirus program setback, while Merck’s KEYTRUDA franchise remains a critical driver for oncology growth.

AI Boom or Bust: Lessons from the Dot-Com Era for Today’s Tech Rally
economy5 days ago

AI Boom or Bust: Lessons from the Dot-Com Era for Today’s Tech Rally

The author argues the current AI investment surge blends real transformation with speculative risk, mirroring past bubbles like the dot-com era and the housing boom: rapid growth and massive leverage from AI champions (Anthropic, OpenAI, Nvidia, Alphabet) fuel lofty valuations, but eventual supply catch-up and tighter financing will likely burst the bubble, followed by a longer-term restructuring; investors are urged to pursue opportunity with caution and risk capital they can afford to lose.

Magnificent Seven Lose Momentum as Concentration Sparks Rebalancing
business6 days ago

Magnificent Seven Lose Momentum as Concentration Sparks Rebalancing

The Magnificent Seven tech giants have underperformed in the first half of 2026, with Nvidia the sole standout while others like Apple, Alphabet, Amazon, and Microsoft are flat or down; rising concerns about high valuations and AI-spending fuel talk of market concentration and the need to diversify beyond the Mag-7, including value stocks, small caps, and non-U.S. equities. While some Mag-7 names remain in top stock lists, analysts warn investors not to rely on them as the market shifts away from their former dominance.